Group 1 - The core point of the news is that Haikang Technology's stock price increased by 5.03%, reaching 51.78 CNY per share, with a total market capitalization of 57.989 billion CNY [1] - Haikang Technology was established on August 26, 2005, and went public on January 17, 2012. The company specializes in the research, development, production, and sales of chemical pharmaceuticals [1] - The main revenue composition of Haikang Technology includes: anesthetic products (39.81%), cooperative product-related income (23.59%), other indications (17.02%), parenteral nutrition (10.32%), antiemetics for tumors (8.15%), and other (supplement) (0.86%) [1] Group 2 - According to data, one fund under CITIC Jiankong holds a significant position in Haikang Technology, with 1 million shares, accounting for 3.63% of the fund's net value [2] - The CITIC Jiankong Medical Reform A fund (002408) has a total scale of 603 million CNY and has achieved a return of 26.89% this year, ranking 3036 out of 8161 in its category [2] - The fund manager, Xie Wei, has been in position for 7 years and 135 days, with the best fund return during his tenure being 90.48% [2]